Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | CCR9 | P51686 | 1/20 | 0.38 |
| ▸ | NQO1 | P15559 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19879597 | 0.83 | MAPK1 (0.47) | CYP11B1CYP11B2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL3819558 | 0.81 | CYP11B1 (0.51) | CYP11B1CYP11B2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL14005150 | 0.80 | AKT1 (0.48) | CHRNB2CHRNA4 | |
| SCHEMBL14005606 | 0.79 | CA12 (0.36) | — | |
| SCHEMBL24768968 | 0.79 | HDAC6 (0.33) | CCR6 | |
| SCHEMBL14004898 | 0.79 | KMT2A (0.36) | CHRNB2CHRNA4 | |
| SCHEMBL14004847 | 0.79 | AKT1 (0.42) | — | |
| SCHEMBL14004852 | 0.79 | AKT1 (0.42) | — | |
| SCHEMBL14005638 | 0.79 | AKT1 (0.42) | — | |
| SCHEMBL91426 | 0.78 | CYP1A1 (0.42) | CYP11B1CYP11B2CHRNB2CHRNA4CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | CYP11B1 53/4885CYP11B2 51/4885CHRNB2 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.